Tradewinds LLC. Sells 444 Shares of Johnson & Johnson (NYSE:JNJ)

Tradewinds LLC. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 17,673 shares of the company’s stock after selling 444 shares during the period. Tradewinds LLC.’s holdings in Johnson & Johnson were worth $2,754,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Roundview Capital LLC increased its holdings in shares of Johnson & Johnson by 19.9% in the fourth quarter. Roundview Capital LLC now owns 70,685 shares of the company’s stock valued at $10,223,000 after purchasing an additional 11,737 shares during the last quarter. Meridian Investment Counsel Inc. boosted its holdings in shares of Johnson & Johnson by 3.7% during the 4th quarter. Meridian Investment Counsel Inc. now owns 23,476 shares of the company’s stock worth $3,395,000 after buying an additional 847 shares during the period. Franklin Resources Inc. grew its stake in Johnson & Johnson by 3.5% in the 4th quarter. Franklin Resources Inc. now owns 17,435,359 shares of the company’s stock valued at $2,521,502,000 after buying an additional 595,290 shares during the last quarter. Family Legacy Inc. lifted its position in Johnson & Johnson by 1.7% during the fourth quarter. Family Legacy Inc. now owns 32,281 shares of the company’s stock worth $4,593,000 after acquiring an additional 531 shares during the last quarter. Finally, Rodgers Brothers Inc. boosted its holdings in shares of Johnson & Johnson by 0.7% during the fourth quarter. Rodgers Brothers Inc. now owns 65,880 shares of the company’s stock worth $9,528,000 after acquiring an additional 463 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Leerink Partners decreased their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company dropped their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.89 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock’s 50-day simple moving average is $159.06 and its 200 day simple moving average is $156.07. The firm has a market capitalization of $399.76 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $2.29 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.